D. E. Shaw & Co. Inc. Sells 4,666,667 Shares of OptiNose, Inc. (NASDAQ:OPTN)

D. E. Shaw & Co. Inc. decreased its stake in OptiNose, Inc. (NASDAQ:OPTN - Free Report) by 93.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 333,333 shares of the company's stock after selling 4,666,667 shares during the period. D. E. Shaw & Co. Inc. owned approximately 3.31% of OptiNose worth $2,227,000 at the end of the most recent reporting period.

Separately, Acorn Capital Advisors LLC acquired a new position in OptiNose during the 4th quarter valued at $2,824,000. Institutional investors own 85.60% of the company's stock.

Insider Buying and Selling

In other OptiNose news, CEO Ramy A. Mahmoud sold 6,376 shares of the company's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $5.29, for a total value of $33,729.04. Following the sale, the chief executive officer now directly owns 126,931 shares in the company, valued at $671,464.99. This represents a 4.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold 8,213 shares of company stock worth $43,643 in the last 90 days. 2.30% of the stock is owned by company insiders.

OptiNose Price Performance

Shares of OptiNose stock remained flat at $9.60 during trading on Monday. The company has a market cap of $97.22 million, a price-to-earnings ratio of -2.29 and a beta of -0.88. The company's 50-day simple moving average is $9.28 and its two-hundred day simple moving average is $7.37. OptiNose, Inc. has a 12-month low of $4.82 and a 12-month high of $20.03.

OptiNose (NASDAQ:OPTN - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.27). The business had revenue of $18.51 million during the quarter, compared to the consensus estimate of $17.70 million. As a group, research analysts expect that OptiNose, Inc. will post -3.22 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Lake Street Capital downgraded shares of OptiNose from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $17.00 to $9.00 in a report on Thursday, March 20th. Piper Sandler restated a "neutral" rating and set a $9.00 price target (down from $15.00) on shares of OptiNose in a research note on Friday, March 21st. Finally, HC Wainwright reissued a "neutral" rating and set a $9.00 price objective on shares of OptiNose in a report on Monday, May 19th.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.